Dako and Epitomics enter into strategic alliance on developing and launching IHC diagnostic monoclonal antibodies
Dako Denmark A/S and Epitomics, Inc. announced that they have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies.
Dako's expertise within the field of human cancer diagnostics, including development of new diagnostic antibodies relevant in identifying, differentiating and characterizing tumors, and Epitomics' exclusive intellectual property rights and expertise within development and production of rabbit monoclonal antibodies are the key ingredients to future development of routine diagnostics, prognostics and predictive immunohistochemical assays, also known as companion diagnostics or PharmacoDiagnostics (PharmDxTM).
Besides the development and launch of new state-of-the-art monoclonal antibodies the strategic alliance between Dako and Epitomics also includes a technology transfer from Epitomic's to Dako's facilities.
The financial terms of the agreement were not disclosed.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets
Sales growth fuels Freeman Technology expansion into new HQ
First field measurements of laughing gas isotopes - Greenhouse gas emissions from soil
Carbon Nanotubes: Endless Opportunities
Sartorius expects profitable growth in 2024 - Double-digit annual sales revenue growth projected through to 2028
A Close Look at Lithium Batteries - Fluorescence probe shows the distribution of active lithium species on lithium metal anodes
Scientists glimpse nanobubbles on super non-stick surfaces - Could lead to design of water-shedding materials for applications in energy, medicine and more
Pharmacoscopy: Next-Generation Microscopy - New possibilities for drug discovery
Cellphone converts into powerful chemical detector - With only $50 worth of components, an ordinary cellphone transforms into a sophisticated scientific instrument, capable of identifying chemicals, drugs, and pathogens